person
Silvia A. N.
- Country
- Spain
- Department
- 1202:Oncologia Médica
Research Overview
assignment
17
Clinical Trials ·
- A Phase 3 Randomized Study of Sacituzumab Govitecan and Pembrolizumab Versus Physician's Choice in Triple Negative Breast Cancer with Residual Invasive Disease
- Evaluation of Trastuzumab and Pertuzumab with FDG-PET Response-Adapted Strategy in HER2-Positive Breast Cancer: The PHERGain Study
- Phase II Study on Sacituzumab Govitecan, Loperamide, and Filgrastim in Metastatic Triple-Negative and Luminal Breast Cancer Patients
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
247
Sites with multiple studies
Has run more than one trial at 247 of 526 partner sites.
Specializations
Breast Cancer Research
The investigator specializes in comprehensive research of breast cancer treatment approaches, with particular focus on different molecular subtypes and stages of the disease.
- HR-positive/HER2-negative early breast cancer
- Triple-negative breast cancer (TNBC)
- Stage I resectable breast cancer
Therapeutic Innovation
The investigator explores innovative therapeutic strategies including minimal residual disease monitoring and neoadjuvant treatment approaches.
- Circulating tumor DNA (ctDNA) analysis
- Pathological response assessment
- Combined therapy approaches
Clinical Assessment Methods
The investigator focuses on evaluating treatment efficacy through various clinical endpoints and biomarker analyses.
- Treatment response monitoring
- Pathological complete response evaluation
- Molecular biomarker assessment
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.